摘要
目的:探讨唑来膦酸治疗原发性骨质疏松症的疗效及安全性。方法:选取2014年1月—2016年1月驻马店市中心医院收治的原发性骨质疏松症患者166例作为研究对象,按随机数字表法分为A组和B组,每组83例。A组患者给予唑来膦酸静脉滴注,B组患者给予阿仑膦酸钠口服,治疗12个月后,观察两组患者的疗效及安全性。结果:A组患者的总有效率为95.18%(79/83),明显高于B组的81.93%(68/83),差异有统计学意义(P<0.05)。治疗后,A组患者腰椎(L_(1—4))、股骨颈、Ward三角区骨密度明显高于本组治疗前及B组,差异均有统计学意义(P<0.05)。A组患者不良反应发生率为4.82%(4/83),B组为6.02%(5/83),两组的差异无统计学意义(P>0.05)。结论:唑来膦酸治疗原发性骨质疏松症的疗效较好,能有效升高骨密度,安全性较高。
OBJECTIVE: To probe into the efficacy and safety of zoledronic acid in treatment of primary osteoporosis. METHODS: 166 patients with primary osteoporosis admitted into Zhumadian Central Hospital from Jan. 2014 to Jan. 2016 were selected to be divided into group A and group B via the random number table, with 83 cases in each. Group A was given azole phosphonic acid by intravenous drip, group B received allen phosphonic acid sodium orally. After treatment of 12 months, the efficacy and safety of two groups were observed. RESULTS : The total effective rate of group A was 95. 18% (79/83), significantly higher than that of group B I81.93% (68/83)], with statically significant difference(P 〈 0. 05). After treatment, lumbar vertebra(L1-4), femoral neck, Ward triangle bone density of group A increased significantly compared with before treatment and group B, with statically significant differenee( P 〈 0. 05). The incidence of adverse drug reactions of group A was 4. 82% (5/83), group B was 6. 02% (5/83), the difference was not statistically significant ( P 〉 0. 05 ). CONCLUSIONS : The efficacy of zoledronic acid in treatment of primary osteoporosis is significant, which can effectively increase the bone mineral density with high safety.
出处
《中国医院用药评价与分析》
2017年第6期763-764,共2页
Evaluation and Analysis of Drug-use in Hospitals of China